Sacral Neuromodulation in Children and Adolescents

Last updated: February 25, 2024
Sponsor: Friedrich-Alexander-Universität Erlangen-Nürnberg
Overall Status: Active - Recruiting

Phase

N/A

Condition

Constipation

Bowel Dysfunction

Fecal Incontinence

Treatment

Invasive Sacral Neuromodulation

Non-invasive Sacral Neuromodulation

Clinical Study ID

NCT04713085
18_20B2
  • Ages 2-17
  • All Genders

Study Summary

The purpose of this study is to assess the efficacy of neuromodulation for treatment of chronic constipation and fecal incontinence in pediatric patients and to evaluate the differences between the invasive vs. non-invasive approach.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age between 2-17 years
  • informed consent
  • chronic constipation according to the ROME IV criteria for more than 3 months with orwithout encopresis/soiling despite underlying diseases such as slow-transitconstipation, rectal evacuation disorders or Hirschsprung's disease.
  • refractory to conventional treatment in an appropriate weight-adapted application (training for bowel movements, lifestyle changes, pelvic floor training,pharmacological options)
  • in cases of Hirschsprung's disease: diagnosis confirmed histologically by rectalbiopsies and in case of resection of an aganglionic segement: period between surgeryand SNM at least 1 year
  • in cases of anorectal malformation or mechanical obstruction: post-surgical status:period between surgery and SNM at least 1 year

Exclusion

Exclusion Criteria:

  • metabolic, inflammatory, and hormonal causes for chronic constipation
  • toxic megacolon or further emergencies, which must be treated surgically
  • sacral fractures or substantial differences in the sacral anatomy
  • inflammatory bowel disorders
  • rectal prolapse
  • neuronal malignancies under medical and radiation therapy
  • seizures

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Invasive Sacral Neuromodulation
Phase:
Study Start date:
January 01, 2019
Estimated Completion Date:
December 31, 2024

Study Description

Patients are selected according to the eligibility requirements. After obtaining informed consent off-label use and potential risks of sacral neuromodulation, all included patients and next of kin give written informed consent to the study.

At baseline, patients are randomized to one of the two predefined subgroups: either invasive sacral neuromodulation or non-invasive sacral neuromodulation. Clinical symptoms and outcome variables are compared regarding the beginning of non-invasive sacral neuromodulation or the implantation of the tined lead electrode. Patients are closely monitored within 6 months. Treatment success is evaluated in routine clinical check-ups (week 4/8/12 and 24) and via specialized questionnaires and bowel movement diaries. Quality of life is evaluated at baseline and after 12 and 24 weeks of treatment.

Connect with a study center

  • Friedrich-Alexander-Universität Erlangen-Nürnberg, Pediatric Surgery

    Erlangen, Bavaria 91054
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.